|
GB202020410D0
|
|
Device and method
|
|
GB202020413D0
|
|
Device and method
|
|
GB202019475D0
|
|
Therapeutic compounds and their use
|
|
GB202018570D0
|
|
Mediators of gene silencing
|
|
GB202018554D0
|
|
Nucleic acid constructs and cells
|
|
GB202018474D0
|
|
Treatment planning system
|
|
WO2021074648A1
|
|
Vector for cancer treatment
|
|
GB202009822D0
|
|
Treatment planning system
|
|
GB202008688D0
|
|
Chimeric antigen receptor cell
|
|
GB202005874D0
|
|
Methods of treatment
|
|
WO2020198670A1
|
|
Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers
|
|
IL273396D0
|
|
4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as cdk inhibitors
|
|
GB202003814D0
|
|
Optimised methods for cleavage of target sequences
|
|
GB201918295D0
|
|
Method and device for detection of prompt gamma emission
|
|
GB201916968D0
|
|
Means and method for treating cancer
|
|
GB201915828D0
|
|
Compounds, compositions and therapeutic uses thereof
|
|
GB201915829D0
|
|
Compounds, compositions and therapeutic uses thereof
|
|
GB201915831D0
|
|
Compounds, compositions and therapeutic uses thereof
|
|
GB201914984D0
|
|
Vector
|
|
GB201914860D0
|
|
Inhibitor compounds
|
